Sarepta Therapeutics to Present at the Evercore ISI 3rd Annual HealthCONx Virtual Conference
November 25, 2020 08:30 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will...
Sarepta Therapeutics Named One of The Boston Globe’s Top Places to Work 2020
November 20, 2020 08:30 ET
|
Sarepta Therapeutics, Inc.
-- Sarepta is honored to be recognized for offering a range of benefits and work-life resources to employees and supporting the local community -- -- Rankings based on confidential survey information...
Sarepta Therapeutics Announces Third Quarter 2020 Financial Results and Recent Corporate Developments
November 05, 2020 16:05 ET
|
Sarepta Therapeutics, Inc.
– Net product sales of $121.4 million, a 23% increase over same quarter of prior year – CAMBRIDGE, Mass., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in...
Sarepta Therapeutics to Commence Dosing of the Next Study with Commercial Process Material for the SRP-9001 Gene Therapy Program for the Treatment of Duchenne Muscular Dystrophy
November 05, 2020 16:02 ET
|
Sarepta Therapeutics, Inc.
-- Dosing with SRP-9001 commercial-process material to proceed following discussions with U.S. FDA -- -- Clinical dosing is expected to begin before the end of 2020 -- CAMBRIDGE, Mass., Nov. 05,...
Sarepta Therapeutics to Present at the 29th Annual Credit Suisse Virtual Healthcare Conference
November 02, 2020 16:30 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will...
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 30, 2020 19:16 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., Oct. 30, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on October 30, 2020...
Sarepta Therapeutics to Announce Third Quarter 2020 Financial Results and Recent Corporate Developments on November 5, 2020
October 29, 2020 08:36 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report third quarter 2020 financial...
Gene Therapy Company AavantiBio Launches with $107 Million Series A Financing from Perceptive Advisors, Bain Capital Life Sciences, RA Capital Management and Sarepta Therapeutics
October 22, 2020 07:30 ET
|
Sarepta Therapeutics, Inc.
AavantiBio will pursue a diversified gene therapy pipeline, including a lead program in Friedreich’s Ataxia (FA), a rare inherited genetic disease characterized by cardiac and central nervous system...
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 30, 2020 18:15 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 30, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on September 30, 2020...
Sarepta Therapeutics Investigational Gene Therapy SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E Shows Sustained Functional Improvements 18-months After Administration
September 28, 2020 08:55 ET
|
Sarepta Therapeutics, Inc.
-- Continued functional improvements were observed at 18 months in the low-dose cohort -- -- First look at functional outcomes in high-dose cohort found improvements 6 months after...